The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.
This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.
Deadlines for Letters of Intent: Feb. 4, 2022; May 20, 2022; Sep. 30, 2022
Funding is open to researchers and clinicians worldwide at:
Up to $5 million based on stage and scope of research. Depending on the availability of funds, in certain cases, well-justified larger budgets may be considered. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
